BCL2 and acute myeloid leukemia: Several drugs did not conform to this trend, including the BCL-2 inhibitor venetoclax6, which was recently approved in combination with HMAs or LDAC for the treatment of AML in newly diagnosed elderly patients or in those unfit for intensive chemotherapy.